Andreessen Horowitz, Madrona and other tech VCs ramp up bets on AI-driven biotech startups as founders from software enter life sciences

Tech venture capital firms like Andreessen Horowitz and Seattle’s Madrona Venture Group are increasingly investing in life-science startups that use AI, machine learning and data science to speed drug discovery and development. Investors are following founders who transitioned from software to biotech—such as Sujal Patel of Nautilus and Terry Myerson of Truveta—seeing reduced perceived risk and new opportunity at this intersection.

MMatt McIlwain SSujal Patel MMadrona UUniversity of Washington